Several novel, emerging, investigational therapeutic, clinical, treatment agents—namely, Vonlerolizumab, RG 7888, Pogalizumab, MOXR 0916—are undergoing, demonstrating, showing promise in the modulation, inhibition, suppression of inflammatory, pathological, aberrant immune, bodily, biological responses. This brief, concise, targeted overview, c